Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCN NASDAQ:ENTX NASDAQ:KZR NASDAQ:MGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.14-0.3%$2.48$1.03▼$8.48$13.59M1.84.31 million shs13,621 shsENTXEntera Bio$1.30-5.5%$1.23$0.91▼$3.22$60.38M1.54209,021 shs94,385 shsKZRKezar Life Sciences$7.34-0.3%$7.09$3.53▼$7.55$54.24M0.466,840 shs46,175 shsMGXMetagenomi$1.42-0.4%$1.45$1.25▼$3.95$53.28M0.63229,598 shs55,530 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics-2.78%-4.83%-9.48%+186.36%-8.16%ENTXEntera Bio+9.60%+15.13%+17.09%+31.73%-37.16%KZRKezar Life Sciences-0.27%+0.68%-0.41%+20.26%+80.13%MGXMetagenomi-0.70%+2.90%+4.41%-7.79%-1.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.14-0.3%$2.48$1.03▼$8.48$13.59M1.84.31 million shs13,621 shsENTXEntera Bio$1.30-5.5%$1.23$0.91▼$3.22$60.38M1.54209,021 shs94,385 shsKZRKezar Life Sciences$7.34-0.3%$7.09$3.53▼$7.55$54.24M0.466,840 shs46,175 shsMGXMetagenomi$1.42-0.4%$1.45$1.25▼$3.95$53.28M0.63229,598 shs55,530 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics-2.78%-4.83%-9.48%+186.36%-8.16%ENTXEntera Bio+9.60%+15.13%+17.09%+31.73%-37.16%KZRKezar Life Sciences-0.27%+0.68%-0.41%+20.26%+80.13%MGXMetagenomi-0.70%+2.90%+4.41%-7.79%-1.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 1.00SellN/AN/AENTXEntera Bio 2.00Hold$9.00594.98% UpsideKZRKezar Life Sciences 1.67Reduce$6.00-18.26% DownsideMGXMetagenomi 2.80Moderate Buy$10.00606.71% UpsideCurrent Analyst Ratings BreakdownLatest CYCN, MGX, ENTX, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/9/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.07M6.57N/AN/A$2.31 per share1.36ENTXEntera Bio$42K1,437.51N/AN/A$0.29 per share4.47KZRKezar Life Sciences$7M7.75N/AN/A$9.57 per share0.77MGXMetagenomi$25.21M2.11N/AN/A$4.22 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$3.53M-$1.16N/AN/AN/A-170.11%-39.23%-35.62%5/15/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.26N/AN/AN/AN/A-66.39%-57.77%5/8/2026 (Estimated)KZRKezar Life Sciences-$56.03M-$7.66N/AN/AN/AN/A-64.42%-54.83%5/12/2026 (Estimated)MGXMetagenomi-$87.87M-$2.37N/AN/AN/A-348.54%-47.14%-33.82%5/12/2026 (Estimated)Latest CYCN, MGX, ENTX, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KZRKezar Life Sciences-$0.98N/AN/AN/A$0.50 millionN/A5/12/2026Q1 2026MGXMetagenomi-$0.60N/AN/AN/A$5.90 millionN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08N/AN/AN/AN/AN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 million3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/27/2026Q4 2025KZRKezar Life Sciences-$1.39-$1.99-$0.60-$1.99$1.67 millionN/A3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A5.155.15ENTXEntera BioN/A6.946.94KZRKezar Life SciencesN/A11.5211.52MGXMetagenomiN/A7.227.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%ENTXEntera Bio14.11%KZRKezar Life Sciences67.90%MGXMetagenomiN/AInsider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%ENTXEntera Bio10.38%KZRKezar Life Sciences10.40%MGXMetagenomi17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataENTXEntera Bio2046.62 million41.78 millionOptionableKZRKezar Life Sciences607.39 million6.62 millionNot OptionableMGXMetagenomi23637.65 million30.95 millionN/ACYCN, MGX, ENTX, and KZR HeadlinesRecent News About These CompaniesMetagenomi (MGX) Projected to Post Quarterly Earnings on TuesdayMay 5 at 11:46 AM | marketbeat.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...April 16, 2026 | markets.businessinsider.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyApril 16, 2026 | globenewswire.comMetagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 14, 2026 | marketbeat.comDid Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 13, 2026 | prnewswire.comMetagenomi Therapeutics: Q4 Earnings SnapshotMarch 5, 2026 | sfgate.comMetagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesMarch 5, 2026 | zacks.comMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comMetagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 4, 2026 | seekingalpha.comMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceFebruary 23, 2026 | globenewswire.comMGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks TranscriptFebruary 18, 2026 | seekingalpha.comIs Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?February 12, 2026 | finance.yahoo.comMGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks TranscriptJanuary 22, 2026 | seekingalpha.comMetagenomi, Inc.: Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookJanuary 12, 2026 | finanznachrichten.deMetagenomi Therapeutics Rebrands to Emphasize Therapeutic FocusJanuary 12, 2026 | tipranks.comMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookJanuary 12, 2026 | globenewswire.comMetagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceDecember 1, 2025 | globenewswire.comMetagenomi (MGX) Price Target Decreased by 13.33% to 8.84November 18, 2025 | msn.comMetagenomi to Present at Jefferies Global Healthcare Conference in LondonNovember 17, 2025 | globenewswire.comMetagenomi culls 25% of its workforce and replaces CEO in reshuffleNovember 13, 2025 | finance.yahoo.comRoundup: Ovid Therapeutics and Metagenomi Announce 2025 Third Quarter Results and Leadership UpdatesNovember 13, 2025 | pharmexec.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCN, MGX, ENTX, and KZR Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.14 -0.01 (-0.35%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Entera Bio NASDAQ:ENTX$1.30 -0.08 (-5.47%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Kezar Life Sciences NASDAQ:KZR$7.34 -0.02 (-0.27%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Metagenomi NASDAQ:MGX$1.42 -0.01 (-0.35%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
